Latest News and Press Releases
Want to stay updated on the latest news?
-
FDA sets PDUFA action date for January 5, 2022 If approved, BXCL501 would represent the first major advancement in the acute treatment of agitation associated with schizophrenia and bipolar disorders...
-
NEW HAVEN, Conn., May 11, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
-
Granted FDA Breakthrough Therapy designation for BXCL501 for the acute treatment of agitation associated with dementia; registrational program expected to begin in 2H 2021 Submitted NDA to FDA for...
-
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
-
NEW HAVEN, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
-
The Campaign, launching during Mental Health Awareness Month, aims to educate healthcare providers on the various signs, symptoms, and levels of severity associated with agitation Interactive...
-
NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
-
Primary safety endpoint achieved in first study of BXCL501 dosed twice-daily over seven days RELEASE results demonstrated numerically improved retention rates in multiple BXCL501 dose cohorts Data...
-
NEW HAVEN, Conn., March 15, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
-
New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation TRANQUILITY...